Go To Fortune 500 Job Source Illinois Job Source Add Your Resume

Abbott Laboratories Develops pharmaceutical and medical products. Headquarters: 100 Abbott Park Rd. Abbott Park, IL 60064 Employees: 90,000 CEO: Miles White Stock Symbol: ABT Website: http://www.abbott.com Company News Career Site Founded in 1900 by Dr. Wallace Calvin Abbott, a Chicago physician, Abbott Laboratories has emerged as one of the world's top health care companies. Today, Abbott discovers, develops, manufactures, and markets products and services that span the continuum of care ­ from prevention and diagnosis, to treatment and cure. More than 5,000 Abbott scientists around the world are committed to developing new, innovative health care technologies in the key therapeutic areas of: diabetes, pain management, respiratory infections, HIV/AIDS, men's and women's health, pediatrics and animal health. HUMIRA is the company's top-selling drug and is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. Niaspan is a top drug in the U.S. for Abbott which is used to treat high cholesterol. Abbott serves customers in over 130 countries. It has more than 100 manufacturing, distribution, research and development, and other locations around the world. The company has research centers in North Chicago, Worcester, MA and Ludwigshafen, Germany. Some of the producs Abbott is working on include: * Oncology o Abbott's oncology pipeline includes targeted therapies that represent promising, unique scientific approaches to treating cancer. Our collaboration with Genentech to develop two Abbott-discovered compounds continues to progress. These compounds include ABT-869, a multi-targeted kinase inhibitor and ABT-263, a Bcl-2 family protein antagonist. o Abbott's oncology research also includes a PARP-inhibitor, which prevents DNA repair in cancer cells, enhancing the effectiveness of current cancer therapies. * Neuroscience o Abbott is conducting innovative research in neuroscience, where we've developed compounds that target receptors in the brain that help regulate mood, memory and other neurological functions to address conditions such as attention deficit hyperactivity disorder, Alzheimer's disease and schizophrenia. Abbott is also working to advance compounds that have the potential to meet the market need for a non-opioid pain therapy. Our work in neuroscience is focused on several promising investigational platforms including NNRs, H3, Calpain and TRPV1, among others. * Immunology o Abbott's scientific experience with the anti-TNF biologic HUMIRA serves as a strong foundation for our continuing research in immunology. Products in development for the treatment of immune-mediated diseases are designed to selectively inhibit proteins that are responsible for inflammation. In addition to our work with IL-12/23, we are working to advance development of our early discovery programs, including oral therapies, as well as other potential biologic targets. o Additionally, our proprietary DVD-ig technology represents an innovative approach that can target multiple disease-causing antigens with a single biologic agent. * Hepatitis C o Abbott's antiviral program is focused on the treatment of hepatitis C, a disease that affects more than 170 million people worldwide. Abbott has several active hepatitis C programs including our partnership with Enanta Pharmaceuticals to develop protease inhibitors as well as an internal polymerase program. * Bioabsorbable Drug-Eluting Stent o Abbott has presented encouraging two-year data from the world's first clinical trial for a fully-bioabsorbable DES to treat coronary artery disease. The bioabsorbable DES is designed to be slowly metabolized by the body and completely absorbed over time. The company had total sales of $38.9 billion in 2011, a 14.3% increase. Net income for the year was $4.72 billion. The company spent $4.1 billion on research and development. Abbott announced plans to separate into two publicly-traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The diversified medical products company will consist of Abbott's branded generic pharmaceutical, devices, diagnostic and nutritional businesses, and will retain the Abbott name. The research-based pharmaceutical company will include Abbott's current portfolio of proprietary pharmaceuticals and biologics and will be named later. Abbott acquired Solvay Pharmaceuticals in 2010 for $6.2 billion. Benefits Abbott offers employees a pension plan, matching 401(k), and cash profit sharing.· Comprehensive benefits package includes health, dental, life and long­term disability insurance. The company recognizes a total of 11 holidays each year, including standard holidays and company­designated holidays. In addition, Abbott offers paid vacation of three weeks per year for new employees (prorated in the first year, based on date of hire). Abbott opened a $10-million child care center at its corporate headquarters in 2001. The child care center is the largest in the state of Illinois. The company also offers an all-day kindergarten program. Updated January 30, 2012